Back to mobile site

Mizuho Reiterates Outperform Rating on Axsome Therapeutics (AXSM)

February 21, 2025 8:36 AM EST Send to a Friend
Mizuho analyst Graig Suvannavejh reiterated an Outperform rating and $195.00 price target on Axsome Therapeutics (NASDAQ: AXSM)The analyst comments "This ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login